Study Finds Viread Advantages in Black Patients An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load after 96 weeks using treatment regimens containing Viread compared to those containing the thymidine analogues Retrovir or Zerit.
March 6, 2007
Twice-Daily Kaletra Possibly Better for Some Patients An ACTG study indicates that once-daily and twice-daily Kaletra are comparable in patients over 48 weeks of treatment, but also suggests that the time to virologic failure using once-daily Kaletra may be shorter among those with high pre-treatment viral loads.
March 1, 2007
Once-Daily Viramune Strikes Out
For several years, researchers have been looking into the possibility of once-daily Viramune dosing. New data, however, suggest that the approved twice-daily schedule will remain the necessary dosing option.
Still No Clear Benefit of Treating Early HIV(Reuters Health) The long-term benefits of starting antiretroviral therapy during primary HIV infection have still not been confirmed. The conflicting results of two studies presented at the 14th CROI highlight the need to clarify this issue.
February 26, 2007
One in 10 Infected with Drug-Resistant HIV
New data from the CDC suggest that approximately one in 10 individuals diagnosed with HIV in recent years was infected with HIV strains resistant to at least one available antiretroviral.
Isentress (MK-0518) Results Prove Promising
Long-awaited data from two Phase III studies of Isentress (MK-0518) indicate that the integrase inhibitor offers “potent and superior” antiretroviral activity to those in desperate need of new treatment options.
Encouraging Data from Two Maraviroc Studies
Early data from two studies of maraviroc, Pfizer's entry inhibitor contender, indicate that the drug is proving useful for treatment-experienced patients with multiple-drug-resistant HIV.
March 5, 2007
Baraclude Induces HIV Drug Resistance New research concludes that hepatitis B virus (HBV) treatment Baraclude (entecavir) is active against HIV, suggesting that that the drug will need to be used with caution in people coinfected with both HIV and HBV.
Study Says Less Fat for Lower Lipids While HIV meds play a role in the high rates of cholesterol and triglyceride problems being seen in HIV-positive people, it also appears that diets rich in fat are likely culprits as well.
February 28, 2007
Shift in Cancer-Related Deaths in HIV
Among those with HIV and on antiretroviral treatment, the risk of dying from a non-AIDS-related cancer is now significantly greater than the risk of dying from an AIDS-related cancer.
February 27, 2007
TH9507 Shows Promise for Lipodystrophy
New data from a Phase III clinical trial of TH9507 suggest that this growth hormone promoter may be associated with moderate decreases in visceral fat with fewer side effects seen in clinical trials involving similar compounds.
February 26, 2007
More Lipoatrophy with Sustiva vs. Kaletra
Data from a clinical trial, presented this past summer, concluded that Sustiva has a few efficacy advantages over Kaletra. New data from the study suggests that Kaletra may have an advantage of its own: less lipaotrophy than Sustiva.
Diary of a Doc: On the Origins of HIV Exclusive to POZ and AIDSmeds, Lloyd Bailey, MD, chimes in with his thoughts on the sophisticated genetic research discussed at CROI that is providing experts with the tools they need to unwrap the mystery of the origins of HIV.
March 2, 2007
Diary of a Doc: New Strategies for HIV-Herpes Coinfection Lloyd Bailey, MD, an HIV specialist with the Spellman Center at St. Vincent's Midtown Hospital in New York City, turns his gaze to the recent spate of data — including reports at CROI — promoting the use of anti-herpes drugs to reduce HIV transmission and disease progression.